Meiji Seika Pharma Co., Ltd., a pharmaceutical company that develops, manufactures, and sells a range of products, announced the establishment of a local subsidiary, “Taiwan Meiji Pharma Co., Ltd.”, on December 18th. This subsidiary will focus on pharmaceutical sales and other related activities in Taiwan and is scheduled to commence operations in February 2025.
Purpose and background of establishment:
Meiji Seika Pharma aims to become “a leading company in Asia in the field of infectious diseases” as part of the “Meiji Group 2026 Vision” targeting the year 2026. By establishing Taiwan Meiji Pharma Co., Ltd. in Taiwan, the fifth largest pharmaceutical market in Asia, we aim to build a business foundation and achieve further growth by supplying products. Taiwan Meiji Pharma Co., Ltd. plans to launch Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor for the treatment of chronic graft-versus-host disease (chronic GVHD), which is currently under application for regulatory approval with the Taiwan Food and Drug Administration (TFDA). Chronic GVHD is a disease that occurs following hematopoietic stem cell transplantation performed for the treatment of leukaemia.
The company will also consider the continuous introduction of other products such as antibiotics and vaccines.
Through Taiwan Meiji Pharma Co., Ltd., Meiji Seika Pharma will stably supply products needed by patients and contribute to the health of the people in Taiwan.
Meiji Seika Pharma is a pharmaceutical company that develops, manufactures, and sells a range of products, including generic drugs, vaccines, and antibacterial drugs. Since it launched penicillin in 1946, has been providing efficacious and high quality pharmaceutical products including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and generic drugs, to meet various medical needs.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!